17th Annual Mild Cognitive Impairment (MCI) Symposium:

Diagnosis, Treatment and Psychosocial Factors Affecting Neurodegenerative and Vascular MCI 

Saturday, JANUARY 19, 2019  ♦  8:00 am – 7:30 pm                                

7:15 am – 8:15	Check-in and Continental Breakfast
8:15 – 8:30	Welcome Notes/Introduction to Symposium	Ranjan Duara, MD, FAAN Mount Sinai Medical Center
8:30 – 9:00	KEYNOTE LECTURE: Recent Advances in the Treatment of Alzheimer’s Disease	Reisa Sperling, MD Harvard Medical School
9:00 – 9:05	Q&A
9:05-11:50	SESSION 1: Interaction of Vascular and Neurodegenerative Disease Chair: Rebecca Gottesman, MD, PhD, Johns Hopkins University
9:05 – 9:10	Session Overview	CHAIR
9:10 – 9:25	Amyloid Deposition in Healthy Aging, Vascular and Neurodegenerative Disease and Genetic Effects	Rebecca Gottesman, MD, PhD Johns Hopkins University
9:25 – 9:30	Q&A
9:30 – 9:45	Amyloid Independent Effects of Vascular Health on Brain Health and Cognitive Impairment	Prashanthi Vemuri, PhD Mayo Clinic
9:45 – 9:50	Q&A
9:50 – 10:05	Late-life Blood Pressure Association with Cerebrovascular and Alzheimer's Disease Pathology	Zoe Arvanitakis, MD Rush University Medical Center
10:05 – 10:10	Q&A
10:10 – 10:40	BREAK
10:40 – 10:55	Insulin Dysregulation and the Pathophysiology of Alzheimer’s Disease	Suzanne Craft, PhD Wake Forest School of Medicine
10:55 – 11:00	Q&A
11:00 – 11:15	Interaction of Vascular and Degenerative Pathology	Denis Dickson, MD Mayo Clinic
11:15 – 11:20	Q&A
11:20 – 11:50	Panel Discussion/Q&A
11:50am – 2:45 pm	SESSION 2: Multimodal Imaging in the Diagnosis of Incipient Neurodegenerative Diseases Co-Chairs: Bradford Dickerson, MD, Massachusetts General Hospital and David Wolk, MD, PhD, University of Pennsylvania
11:50 am – 11:55	Session Overview	Co-Chairs
11:55 – 12:10	The Promise and Pitfalls of Imaging Biomarkers in the Diagnostic Evaluation of Research Participants with MCI	Bradford Dickerson, MD Massachusetts General Hospital
12:10 – 12:15	Q&A
12:15 – 12:30	Multimodal Imaging in the Diagnosis of Incipient Neurodegenerative Disease	David Wolk, MD University of Pennsylvania
12:30 – 12:35	Q&A
12:35 – 1:35	LUNCH
1:35 – 1:50	Doctor, Doctor: A Diagnostic Case Comparison of Misremembering, Misbehavior, Misunderstanding, and Mis- and Dys-Execution involving Two Doctoral Professionals	Alireza Atri, MD, PhD Banner Sun Health Research Institute
1:50 – 1:55	Q&A
1:55 – 2:10	Case Studies	Stephen Salloway, MD Alpert Medical School of Brown University
2:10 – 2:15	Q&A
2:15 – 2:45	Panel Discussion/ Q&A	Ronald Petersen, MD, PhD Mayo Clinic
2:45 – 5:25	SESSION 3: Neurorehabilitation for MCI Chair: Benjamin Hampstead, PhD, University of Michigan
2:45 – 2:50	Overview	CHAIR
2:50 – 3:20	KEYNOTE LECTURE: Cognitive Rehabilitation In MCI: Behavioral and fMRI Studies	Krishnankutty Sathian, MD, PhD Penn State Neuroscience Institute
3:20 – 3:25	Q&A
3:25 – 3:40	Neuromodulation as a Rehabilitation Tool in Aging, MCI and Dementia	Benjamin Hampstead, PhD University of Michigan
3:40 – 3:45	Q&A
3:45 – 4:15	BREAK
4:15 – 4:30	Cognitive Training in MCI and SCI: Impact on Cognition, Strategy Use and Virtual Reality Measures of Real-life Cognition	Sylvie Belleville, PhD University of Montreal
4:30 – 4:35	Q&A
4:35 – 4:50	Comparative Effectiveness of Behavioral Interventions for MCI	Melanie Chandler, PhD Mayo Clinic
4:50 – 4:55	Q&A
4:55 – 5:25	Panel Discussion/ Q&A	Michael Marsiske, PhD University of Florida
5:25 – 7:30	Networking Reception

The Annual Early Alzheimer’s Diagnostic and Treatment Workshop:

Acculturative Stress, Discrimination and Cognitive Performance in Older Adults

Sunday, JANUARY 20, 2019 ♦ 8:30 am – 1:30 pm                                    

7:30 am – 8:30	Continental Breakfast and Check-in
8:30 – 8:35	Introduction	Ranjan Duara, MD, FAAN Mount Sinai Medical Center
8:35 – 8:40	Workshop Overview	CHAIR: Lisa Barnes, PhD Rush University
8:40 – 9:10	KEYNOTE LECTURE: Psychosocial Stress and Its Impact on Aging Outcomes	Lisa Barnes, PhD Rush University
9:10 – 9:15	Q&A
9:15 – 9:35	The Impact of Culture and Education on Neuropsychological Measurements	Monica Rosselli, PhD Florida Atlantic University
9:35 – 9:40	Q&A
9:40 – 10:00	Association between Migration and Cognitive Function among Middle-aged and Older Adults	Hanzhang Xu, PhD, RN Duke University School of Nursing
10:00 – 10:05	Q&A
10:05 – 10:35	BREAK
10:35 – 10:55	Lessons learned from the ESCAPE Study (Effects of Stress on Cognitive Aging, Physiology, and Emotion)	Stacey Scott, PhD Stony Brook University
10:55 – 11:00	Q&A
11:00 – 11:20	Acculturation, Cognition, and Brain Imaging Correlates in a Diverse Cohort	Rosie Curiel, PhD University of Miami
11:20 – 11:25	Q&A
11:25 – 12:00 pm	Panel Discussion/Q&A	Moderator: Miriam Rodriguez, PhD Albizu University
12:00 – 1:00	LUNCH

The Annual Alzheimer’s Public Educational Forum:

Mild Cognitive Impairment: Early Diagnosis and the Impact of Stress, Culture and Memory Training

Sunday, JANUARY 20, 2019 ♦ 1:30 pm – 5:40 pm                                 

1:00 - 1:30pm	Check-in and Refreshments
1:30 – 1:35	Welcome Notes	Ranjan Duara, MD, FAAN Mount Sinai Medical Center
1:35 – 5:00	EDUCATIONAL FORUM: Mild Cognitive Impairment: Early Diagnosis and the Impact of Stress, Culture and Memory Training CHAIR: Mary Ganguli, MD, MPH University of Pittsburgh
1:35 – 1:40	Overview	CHAIR
1:40 – 2:10	KEYNOTE LECTURE: Changing our understanding of Alzheimer’s disease from inevitable, untreatable, and incurable, to preventable, treatable and curable	Todd Golde, MD, PhD McKnight Brain Institute
2:10 – 2:15	Q&A
2:15 – 2:30	Vascular and Degenerative Causes of Cognitive Impairment: How Are They Linked?	Rebecca Gottesman, MD, PhD Johns Hopkins University
2:30 – 2:35	Q&A
2:35 – 2:50	Detect of the Very Earliest Stages of Alzheimer’s Disease Using Cognitive Testing and Brain Imaging	David Loewenstein, PhD University of Miami
2:50 – 2:55	Q&A
2:55 – 3:25	BREAK
3:25 – 3:40	Cognitive Training in the Older Adults and in MCI	Sylvie Belleville, PhD University of Montreal
3:40 – 3:45	Q&A
3:45 – 4:00	Culture, Stress and Impact on Cognitive Performance	Lisa Barnes, PhD Rush University
4:00 – 4:05	Q&A
4:05 – 4:50	Panel Discussion and Q&A
4:50 – 5:00	Closing Notes	Ranjan Duara, MD, FAAN Mount Sinai Medical Center

SUPPORTERS

---

 

This event was graciously underwritten by Marilyn and the late Myers Girsh.

---

 

The event was presented by:

Wien Center for Alzheimer’s Disease and Memory Disorders at Mount Sinai Medical Center.

http://www.msmc.com/neurosciences/wien-center-for-alzheimers-disease-memory-disorders

and

1Florida ADRC

---

The event was made possible by educational grants from

 

Lilly USA, LLC

www.lillygrantoffice.com

and with support from

Biogen

www.biogen.com

Life Molecular Imaging

https://life-mi.com/

 

---

 

MEDIA PARTNERS

13th Human Amyloid Imaging Conference

13th Drug Discovery for Neurodegeneration Conference

Alzheimer’s Association SE Florida Chapter

American Board of Professional Neuropsychology

American Neuropsychiatric Association

Care Weekly

Dutch Society for Neuropsychology

Geriatrics Journal

German Society for Neuropsychology

Hispanic Neuropsychological Society

International Neuropsychology Society

Journal of Alzheimer’s Disease

Karger Publishers

The Int’l Conference on Frontotemporal Dementia

16th Annual Mild Cognitive Impairment (MCI) Symposium:

Genetics, Cognitive Reserve and Behavior in MCI and Alzheimer’s Disease

Saturday, JANUARY 20, 2018  ♦  8:00 am – 7:30 pm                                

7:15 am – 8:15	Check-in and Continental Breakfast
8:15 – 8:30	Welcome Notes/Introduction to Symposium	Ranjan Duara, MD, FAAN (bio) Mount Sinai Medical Center
8:30-11:30	SESSION 1: APOE4, Non E4 and Epigenetics of LOAD Chair: Andrew Saykin, PsyD, ABCN Indiana University
8:30 – 8:35	Session Overview	Andrew Saykin, PsyD, ABCN (bio) Indiana University
8:35 – 9:05	KEYNOTE LECTURE: APOE4, Non E4 and Epigenetics of LOAD and Vascular Cognitive Impairment	Sudha Seshadri, MD (bio/abstract) Boston University
9:05 – 9:10	Q&A
9:10 – 9:25	Role of Apolipoprotein E in Neurodegenerative Dementia	Henrietta Nielsen, PhD (bio/abstract) Stockholm University
9:25 – 9:30	Q&A
9:30 – 9:45	Polygenic Hazard Score in LOAD	Chin Hong Tan, PhD (bio/abstract) University of California San Francisco
9:45 – 9:50	Q&A
9:50 – 10:05	Epigenetics in Alzheimer’s Disease	Debomoy Lahiri, PhD (bio/abstract) Indiana University
10:05 – 10:10	Q&A
10:10 – 10:40	BREAK
10:40 – 10:55	Imaging Genetics of APOE and Non-APOE factors in LOAD	Andrew Saykin, PsyD, ABCN (bio/abstract) Indiana University
10:55 – 11:00	Q&A
11:00-11:30	Panel Discussion/Q&A
11:30am – 2:40 pm	SESSION 2: Cognitive and Brain Reserve Chair: Ronald Petersen, MD, PhD Mayo Clinic
11:30 am – 11:35	Session Overview	Ronald Petersen, MD, PhD (bio) Mayo Clinic
11:35 – 12:05	KEYNOTE LECTURE: Brain and Cognitive Reserve: Epidemiology, Imaging and Biological Mechanisms	Yaakov Stern, PhD (bio/abstract) Columbia University
12:05 pm - 12:10 pm	Q&A
12:10 – 12:25	The Role of Cognitive Reserve in the Neuropsychological Diagnosis of Normal and Abnormal Aging	Dorene Rentz, PsyD (bio/abstract) Harvard Medical School, BWH, MGH
12:25 –12:30	Q&A
12:30 –1:30	LUNCH
1:30 –1:45	The Impact of Cognitive Reserve on CSF Biomarkers of AD	Sanjay Asthana, MD (bio/abstract) University of Wisconsin
1:45 – 1:50	Q&A
1:50 – 2:05	Behavioral Markers of Cognitive Reserve	Robert Wilson, PhD (bio/abstract) Rush University
2:05 – 2:10	Q&A
2:10 – 2:40	Panel Discussion/ Q&A	Glenn Smith, PhD (bio) University of Florida
2:40 – 5:20	SESSION 3: Mild Behavioral Impairment Chair: Mary Ganguli, MD, MPH University of Pittsburgh
2:40 – 2:45	Overview	Mary Ganguli, MD, MPH (bio) University of Pittsburgh
2:45 – 3:15	KEYNOTE LECTURE: Mild Behavioral Impairment (MBI): Symptoms, Prodrome, or False Alarm?	Constantine Lyketsos, MD (bio/abstract) Johns Hopkins Medicine
3:15 – 3:20	Q&A
3:20 – 3:35	Neuropsychiatric Symptoms as Predictors of MCI and Dementia: Epidemiologic Evidence	Yonas Geda, MD (bio/abstract) Mayo Clinic
3:35 – 3:40	Q&A
3:40 – 4:10	BREAK
4:10 – 4:25	Are there Neuroimaging Signatures for MBI? A Review of the Five Domains	Zahinoor Ismail, MD, FRCPC (bio/abstract) University of Calgary
4:25 – 4:30	Q&A
4:30 – 4:45	Association of Amyloid-β with Depression-Related Symptoms in Cognitively Normal Older Adults	Nancy Donovan, MD (bio/abstract) Harvard Medical School, Brigham and Women's Hospital
4:45 – 4:50	Q&A
4:50 – 5:20	Panel Discussion/ Q&A
5:20 – 7:30	Networking Reception

The Annual Early Alzheimer’s Diagnostic and Treatment Workshop:

Bilingualism, Neuropsychology, Imaging and Treatment in MCI and AD

Sunday, JANUARY 21, 2018 ♦ 8:30 am – 1:30 pm                                    

7:30 am – 8:30	Continental Breakfast and Check-in
8:30 – 8:35	Welcome Notes	Ranjan Duara, MD, FAAN (bio) Mount Sinai Medical Center
8:35 – 9:05	SPECIAL LECTURE: Treatment of Alzheimer’s Disease: Where We Are and Prospects for the Future	Serge Gauthier, MD, FRCPC (bio/abstract) McGill University
9:05 – 9:10	Q&A
9:10 – 12:10	WORKSHOP: Bilingualism, Neuropsychology, Imaging and Treatment in MCI and AD CHAIR: Monica Rosselli, PhD Florida Atlantic University
9:10 – 9:15	Introduction	Monica Rosselli, PhD (bio/abstract) Florida Atlantic University
9:15 – 9:45	KEYNOTE LECTURE: Bilingualism: Consequences for the Progression of MCI	Howard Chertkow, MD (bio/abstract) McGill University
9:45 – 9:50	Q&A
9:50 – 10:05	Active Bilingualism as a Cognitive Reserve Mechanism in Mild Cognitive Impairment	Marco Calabria, PhD (bio/abstract) Pompeu Fabra University
10:05 – 10:10	Q&A
10:10 – 10:40	BREAK
10:40 – 10:55	Structural MRI and Memory in Bilinguals and Monolinguals with MCI	Monica Rosselli, PhD (bio/abstract) Florida Atlantic University
10:55 – 11:00	Q&A
11:00 – 11:15	Bilingualism and Dementia Prevention: Neuroprotection as Studied in The Brain	Jubin Abutalebi, MD, PhD (bio/abstract) Vita-Salute San Raffaele University
11:15 – 11:20	Q&A
11:20 – 11:35	Neural Efficiency in Lifelong Bilinguals Studied by Functional MRI	Brian Gold, PhD (bio) University of Kentucky
11:35 – 11:40	Q&A
11:40 – 12:10	Panel Discussion/Q&A	Moderator: David Loewenstein, PhD (bio) University of Miami
12:10 – 1:10	LUNCH

The Annual Alzheimer’s Public Educational Forum:

Genetics, Cognitive Reserve, Behavior, Bilingualism and Treatment in MCI and Alzheimer’s Disease

Sunday, JANUARY 21, 2018 ♦ 1:30 pm – 5:40 pm                                 

1:00 - 1:30pm	Check-in and Refreshments
1:30 – 1:35	Welcome Notes	Ranjan Duara, MD, FAAN (bio) Mount Sinai Medical Center
1:35 – 5:00	EDUCATIONAL FORUM: Genetics, Cognitive Reserve, Behavior, Bilingualism and Treatment in MCI and AD CHAIR: David Loewenstein, PhD University of Miami
1:35 – 1:40	Overview	David Loewenstein, PhD (bio) University of Miami
1:40 – 2:10	KEYNOTE LECTURE: Advances in the Treatment of Alzheimer’s Disease	Serge Gauthier, MD, FRCPC (bio/abstract) McGill University
2:10 – 2:15	Q&A
2:15 – 2:30	Genetics of Late Onset Alzheimer’s Disease	Andrew Saykin, PsyD, ABCN (bio/abstract) Indiana University
2:30 – 2:35	Q&A
2:35 – 2:50	The Role of Cognitive Reserve in Normal and Abnormal Aging	Dorene Rentz, PsyD (bio/abstract) Harvard Medical School, BWH, MGH
2:50 – 2:55	Q&A
2:55 – 3:25	BREAK
3:25 – 3:40	Mood, Personality, and Behavior Changes in Early Alzheimer's Disease	Mary Ganguli, MD, MPH (bio/abstract) University of Pittsburgh
3:40 – 3:45	Q&A
3:45 – 4:00	The Importance of Bilingualism for Cognitive Aging and Development of Dementia	Howard Chertkow, MD (bio/abstract) McGill University
4:00 – 4:05	Q&A
4:05 – 4:50	Panel Discussion and Q&A
4:50 – 5:00	Closing Notes	Ranjan Duara, MD, FAAN (bio) Mount Sinai Medical Center

SUPPORTERS

---

This event is graciously underwritten by Marilyn and the late Myers Girsh.

---

The event is presented by:

Wien Center for Alzheimer’s Disease and Memory Disorders at Mount Sinai Medical Center.

http://www.msmc.com/neurosciences/wien-center-for-alzheimers-disease-memory-disorders

---

The event is made possible by educational grants from

Lilly USA, LLC.

www.lillygrantoffice.com

and with support from

Biogen

www.biogen.com

---

MEDIA PARTNERS

12th Human Amyloid Imaging Conference

12th Drug Discovery for Neurodegeneration Conference

Alzheimer’s Association SE Florida Chapter

American Board of Professional Neuropsychology

American Neuropsychiatric Association

Care Weekly

Dutch Society for Neuropsychology

Geriatrics Journal

German Society for Neuropsychology

Hispanic Neuropsychological Society

International Neuropsychology Society

Journal of Alzheimer’s Disease

Karger Publishers

The Int’l Conference on Frontotemporal Dementia

15th Annual Mild Cognitive Impairment (MCI) Symposium:

Biological and Clinical Aspects of Disorders Presenting as MCI

Saturday, JANUARY 14, 2017  ♦  8:00 am – 7:30 pm                                

7:15 am – 8:15	Check-in and Continental Breakfast
8:15 – 8:30	Welcome Notes/Introduction to Symposium	Ranjan Duara, MD Mount Sinai Medical Center, Miami Beach, FL
8:30-11:25	SESSION 1: Seeding and Spread in Neurodegenerative Diseases Chair: Todd Golde, MD, PhD University of Florida, Gainesville, FL Alzheimer’s disease is the most frequent pathology associated with cognitive impairment in older adults. Rare disorders such as Creutzfeldt–Jakob disease (CJD) are known to be seeded and propagated by infectious agents known as prions. Evidence is emerging that common neurodegenerative disorders such as AD may also involve seeding (by misfolded proteins) and subsequent spreading among vulnerable neuronal paths. The precise mechanisms are unclear. This session will first explore the findings at the cellular level for seeding and propagation, including possible therapeutic targets. Clinical evidence from imaging studies for spreading of neurodegeneration in a stereotypical pattern and the clinical implications of this phenomenon will also be presented.
8:30 – 8:35	Session Overview	Todd Golde, MD, PhD University of Florida, Gainesville, FL
8:35 – 9:05	KEYNOTE LECTURE: Mechanisms of Protein Seeding in Neurodegenerative Diseases	Lary Walker, PhD Emory University, Atlanta, GA
9:05 – 9:10	Q&A
9:10 – 9:25	Prion-like Propagation of Alpha-synuclein Aggregates in the Brain of Wild-type Mice	Nolwen Rey, PhD, Van Andel Institute, Grand Rapids, MI
9:25 – 9:30	Q&A
9:30 – 9:45	Prion-like Mechanisms of Disease Progression on Alzheimer’s Disease: New Therapeutic Opportunities	David Borchelt, PhD University of Florida, Gainesville, FL
9:45 – 9:50	Q&A
9:50 – 10:15	BREAK
10:15 – 10:30	Network-Based Spread in AD: Evidence from Multi-Modal Human Neuroimaging	Gil Rabinovici, MD University of California San Francisco, CA
10:30 – 10:35	Q&A
10:35 – 10:50	Clinicopathologic Heterogeneity of Neurofibrillary Tangle Patterns	Melissa Murray, PhD Mayo Clinic, Jacksonville, FL
10:50 – 10:55	Q&A
10:55-11:25	Panel Discussion/Q&A
11:25 am – 3:15 pm	SESSION 2: Progression Rates in Preclinical and Prodromal Neurodegenerative Disorders Chair: Ronald Petersen, MD, PhD Mayo Clinic, Rochester, MN Among patients with preclinical or prodromal AD and other neurodegenerative disease the mode of progression of the disease may be variable, resulting in variable pathological and clinical subtypes of the disease. Baseline measures using fluid biomarkers, imaging and sensitive neurocognitive assessments, can increase the accuracy of predicting future cognitive decline at an early stage of disease. This session will explore these variable pathological subtypes and will describe the utility of clinical symptoms, genetics, functional and structural MRI, amyloid PET and Tau PET in predicting clinical progression of early AD.
11:25 am – 11:30	Session Overview	Ronald Petersen, MD, PhD Mayo Clinic, Rochester, MN
11:30 – 12:00	KEYNOTE LECTURE: Community Predictors of Progression in Preclinical and MCI Due to AD	Ronald Petersen, MD, PhD Mayo Clinic, Rochester, MN
12:00 pm - 12:05 pm	Q&A
12:05 – 12:20	Cognitive Decline in Preclinical Alzheimer’s Disease	Beth Mormino, PhD Massachusetts General Hospital, Boston, MA
12:20 –12:25	Q&A
12:25 –12:40	Imaging Predictors of Progression (Amyloid and Tau PET)	Adam Fleisher, MD Eli Lilly & Co., Inc., Indianapolis, IN
12:40 – 12:45	Q&A
12:45-1:45	LUNCH
1:45 – 2:00	CSF Predictors of Disease Progression	Anne Fagan, PhD Washington University in St Louis, MO
2:00 – 2:05	Q&A
2:05 – 2:20	Modeling Progression in Neurodegenerative Diseases Using Network Connectivity	Ashish Raj, PhD Weill Medical College of Cornell University, New York, NY
2:20 – 2:25	Q&A
2:25 – 2:45	Longitudinal Progression of Biomarkers and Clinical Symptoms in Dominantly Inherited AD	Eric McDade, DO, and Jason Hassenstab, PhD Washington University in St Louis, MO
2:45 – 2:50	Q&A
2:50 – 3:20	Panel Discussion/ Q&A
3:20 – 3:45	BREAK
3:45 – 6:15	SESSION 3: Sleep Disorders and MCI Chair: Steven DeKosky, MD University of Florida, Gainesville, FL Subjects with MCI and dementia are more likely to have sleep disorders than subjects with normal cognition. Specific patterns of sleep disorders are characteristic of some neurodegenerative diseases, such as Lewy Body Dementia and Parkinson Dementia. Sleep is important for consolidating memory and other cognitive function. During sleep there is a change in the cellular architecture of the brain, opening channels which allow toxic substances, including beta-amyloid to be removed from the brain. Evidence for a causal relationship between poor sleep and future cognitive decline is provided by epidemiological, clinical and brain imaging studies. Some studies also suggest that sleep can be protective against AD.
3:45 – 3:50	Session Overview	Steven DeKosky, MD University of Florida, Gainesville, FL
3:50 – 4:05	Sleep, Aging, and Brain Health: Implications for Prevention	Adam Spira, PhD Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
4:05 – 4:10	Q&A
4:10 – 4:25	Poor Sleep before Dementia: A Risk Factor for Cognitive Decline and Clinical Conversion?	Bryce Mander, PhD University of California, Berkeley, CA
4:25 – 4:30	Q&A
4:30 – 5:00	KEYNOTE LECTURE: The Glymphatic System, Sleep and Neurodegeneration	Jeffrey Iliff, PhD OHSU, Portland, OR
5:00 – 5:05	Q&A
5:05 – 5:20	Obstructive Sleep Apnea, MCI and AD: Is there a Direct Link?	Ricardo Osorio, MD New York University Center on Brain Health, NY, NY
5:20 – 5:25	Q&A
5:25 – 5:40	REM Sleep Behavior Disorder and Neurodegenerative Disease	Michael Howell, MD University of Minnesota, Minneapolis, MN
5:40 – 5:45	Q&A
5:45 – 6:15	Panel Discussion/ Q&A
6:15 – 8:00	Networking Reception

The Annual Early Alzheimer’s Diagnostic and Treatment Workshop:

Assessment of Neuropsychological Test Performance in Cross Cultural Studies

Sunday, JANUARY 15, 2017 ♦ 8:30 am – 1:30 pm                                    

7:30 am – 8:30	Continental Breakfast and Check-in
8:30 – 12:30	WORKSHOP: Assessment of Neuropsychological Test Performance in Cross Cultural Studies CHAIR: Monica Rosselli, PhD Florida Atlantic University This workshop will present genetic, clinical and neuroimaging findings conducted in Colombia on the largest known cohort of carriers of a rare autosomal dominant mutation with early age of onset. Furthermore, the prevalence of MCI and AD in Latin America will be analyzed. Additional presentations will explore the clinical validity of of neuropsychological tests for Spanish and English speakers living in the US who are diagnosed with MCI and early AD. Cultural and demographic variables in the diagnosis of abnormal aging will be discussed. The use of neuroimaging to better understand the relationship of structural brain changes to performance on neuropsychological tests among Spanish and English speakers will also be presented.
8:30 – 8:35	Welcome Notes	Ranjan Duara, MD, Mount Sinai Medical Center, Miami Beach, FL
8:35 – 8:40	Introduction	Monica Rosselli, PhD Florida Atlantic University, Davie, FL
8:40 – 9:05	KEYNOTE LECTURE: The E280A PS1 Paisa Mutation and Biomarkers	Francisco Lopera, MD Universidad de Antioquia, Medellín, Colombia
9:05 – 9:10	Q&A
9:10 – 9:25	Brain imaging and Biomarker Abnormalities in Cognitively-unimpaired Individuals with Autosomal-dominant Alzheimer's Disease	Yakeel Quiroz, PhD Massachusetts General Hospital, Boston, MA
9:25 – 9:30	Q&A
9:30 – 9:45	The Development of Novel Cognitive Stress Paradigms for Detection of Early Cognitive Impairment in Cross-Cultural Research	David Loewenstein, PhD University of Miami, Miami, FL
9:45 – 9:50	Q&A
9:50 – 10:05	Neuropsychological Test Performance in Spanish and English Speakers with Normal Cognition and MCI	Rosie Curiel, PsyD University of Miami, Miami, FL
10:05 – 10:10	Q&A
10:10 – 10:40	BREAK
10:40 – 10:55	Culture, Bilingualism, Neuropsychological Tests, and Biomarkers in MCI and early AD	Monica Rosselli, PhD Florida Atlantic University, Davie, FL
10:55 – 11:00	Q&A
11:00 – 11:15	Education and Late-life Cognitive Health in Diverse Populations	Dan Mungas, PhD University of California, Davis, CA
11:15 – 11:20	Q&A
11:20 – 11:35	MCI in Latin American Countries	Ricardo Nitrini , MD, PhD FMUSP, São Paulo SP, Brazil
11:35 – 11:40	Q&A
11:40 am – 12:00 pm	Concluding Remarks	Vladimir Hachinski, MD, DSc University of Western Ontario, London, ON
12:00 – 12:30	Panel Discussion/Q&A Moderator: Oscar Lopez, MD University of Pittsburgh, Pittsburgh, PA
12:30 – 1:30	LUNCH

The Annual Alzheimer’s Public Educational Forum:

New Concepts in Alzheimer’s Cause, Progression and Therapy

Sunday, JANUARY 15, 2017 ♦ 1:30 pm – 5:40 pm                                 

1:00 - 1:30pm	Check-in and Refreshments
1:30 – 5:00	EDUCATIONAL FORUM: New Concepts in Alzheimer’s Cause, Progression and Therapy Chair: David Loewenstein, PhD University of Miami, Miami, FL This event is intended for the public at large, including individuals at-risk for AD, their family members, as well as professionals from various fields who may be interested in an up-to-date review of some aspects of AD research. The forum will allow the audience to interact with top scientists in the field in the presence of a moderator. This educational segment aims to provide information about the latest research in the field of AD, including an on-going prevention trial, several epidemiological studies of aging, and investigations showing the effect of sleep on memory and mental health.
1:30 – 1:40	Welcome Notes	Ranjan Duara, MD Mount Sinai Medical Center, Miami Beach, FL
1:40 – 2:10	KEYNOTE LECTURE: Research to Clinic: Alzheimer's Disease Participation in Clinical Trials	Maria Carrillo, PhD Alzheimer’s Association, Chicago, IL
2:10 – 2:15	Introduction	David Loewenstein, PhD University of Miami, Miami, FL
2:15 – 2:30	Basis of Therapeutic Trials in Alzheimer’s Disease	Reisa Sperling, MD Massachusetts General Hospital, Boston, MA
2:30 – 2:35	Q&A
2:35 – 2:50	Declining Incidence of Alzheimer’s Disease – Is it Real?	Mary Ganguli, MD, MPH University of Pittsburgh, Pittsburgh, PA
2:50 – 2:55	Q&A
2:55 – 3:10	How Do Neurodegenerative Diseases Progress?	Lary Walker, PhD Emory University, Atlanta, GA
3:10 – 3:15	Q&A
3:15 – 3:45	BREAK
3:45 – 4:00	The Glymphatic System and the Brain	Jeffrey Iliff, PhD OHSU, Portland, OR
4:00 – 4:05	Q&A
4:05 – 4:20	Why Sleep Should Not Be Ignored in Alzheimer's Disease	Bryce Mander, PhD University of California, Berkeley, CA
4:20 – 4:25	Q&A
4:25 – 4:55	Panel Discussion and Q&A
4:55 – 5:00	Closing Notes	Ranjan Duara, MD Mount Sinai Medical Center, Miami Beach, FL

SUPPORTERS

---

This event is graciously underwritten by Marilyn and the late Myers Girsh.

---

The event is presented by:

Wien Center for Alzheimer’s Disease and Memory Disorders at Mount Sinai Medical Center.

http://www.msmc.com/neurosciences/wien-center-for-alzheimers-disease-memory-disorders

---

The event is made possible by educational grants from

Lilly USA, LLC.

www.lillygrantoffice.com

and with support from

Biogen

www.biogen.com

---

MEDIA PARTNERS

11th Human Amyloid Imaging Conference

ADDF’s 11th Annual Drug Discovery for Neurodegeneration Conference

Alzheimer’s Association SE Florida Chapter

Alliance for Aging, Inc.

American Neuropsychiatric Association

Geriatrics Journal

Hispanic Neuropsychological Society

Journal of Alzheimer’s Disease

Karger Publishers

Latino Alzheimer’s & Memory Disorders Alliance

Latino Center on Aging

14th Annual Mild Cognitive Impairment (MCI) Symposium:

Risk Factors for Cognitive Decline: Cardiovascular Disease, Inflammation and Subjective Symptoms

Saturday, JANUARY 16, 2016  ♦  8:00 am – 7:30 pm                                

7:00-8:00am	Continental Breakfast and Check-in
8:00-8:15	Introduction to the Symposium	Ranjan Duara, MD, Mount Sinai Medical Center
8:15-9:00	KEYNOTE LECTURE: Genes, AD Pathology, Cerebrovascular Disease, and AD Dementia	David A. Bennett, MD Rush University Medical Center
9:00-12:30	MINISYMPOSIUM 1: Vascular Disease, Neuroinflammation and Cognition Chair: Charles S. DeCarli, MD, University of California, Davis
9:00-9:20	Aging, Alzheimer Disease and Vascular Pathology: Which are the Determinants of Cognitive Impairment?	Charles Duyckaerts, MD, PhD Hôpital Pitié Salpêtrière
9:20-9:40	Innate Immune Activation in Neurodegenerative Disease: Differential Effects on Amyloid and Tau Pathology	David Morgan, PhD University of South Florida
9:40-10:00	Genetic Pathways Linking Neuroinflammation, Vascular Disease and Neurodegeneration	Sudha Seshadri, MD Boston University
10:00-10:30	BREAK
10:30-10:50	Impact of Vascular Risk Factors on Cognition Independent of Amyloid and MRI Measures of AD and CVD	Charles S. DeCarli, MD University of California, Davis
10:50-11:10	Systemic Inflammation Triggers Acute Delirium, Brain Injury and Contributes to Accelerated Neurodegeneration	Colm Cunningham, PhD Trinity College Dublin
11:10-11:30	Markers of Inflammation and Immune Activation, Small Vessel Disease, Amyloid Deposition and Progression to Dementia in Non-Demented Individuals	Oscar Lopez, MD University of Pittsburgh
11:30-11:50	Lifestyle Intervention To Prevent Cognitive Impairment	Miia Kivipelto, MD, PhD Karolinska Institutet
11:50am-12:50pm	MiniSymposium 1 Discussion Moderator: Vladimir Hachinski, CM, MD, DSc, FRCP, University of Western Ontario
12:50-1:50	LUNCH
1:50-5:20	MINISYMPOSIUM 2: Subjective Cognitive Impairment: Epidemiology, Biomarkers, and Progression Chair: Mary Ganguli, MD, MPH, University of Pittsburgh
1:50-2:10	The Epidemiological Relevance of Subjective Cognitive Decline	Ingmar Skoog, PhD University of Gothenburg
2:10-2:30	Subjective Cognitive Concerns and Biomarker Evidence of Preclinical Alzheimer’s Disease	Rebecca Amariglio, PhD Massachusetts General Hospital/Brigham and Women's Hospital
2:30-2:50	Subjective Cognitive Impairment, Neuroticism and Brain Amyloid Load	Beth Snitz, PhD University of Pittsburgh
2:50-3:10	Family History, Subjective Memory Complaints and Brain Amyloid Load in the ADNI Study	Andrew J. Saykin, PsyD Indiana University School of Medicine
3:10–3:40	BREAK
3:40–4:00	Neuropathology Among Cognitively Normal Brain Donors, With & Without Subjective Memory Complaints	Frederick Schmitt, PhD University of Kentucky
4:00-4:20	APOE e4, Subjective Memory Symptoms and Cognitive Decline	Marwan Sabbagh, MD Barrow Neurological Institute
4:20-5:20	MiniSymposium 2 Discussion Moderator: Ronald C. Petersen, MD, PhD, Mayo Clinic
5:20-7:30	NETWORKING RECEPTION

The Annual Early Alzheimer’s Diagnostic and Treatment Workshop:

Diagnosis of Preclinical and Prodromal Alzheimer’s Disease

Sunday, JANUARY 17, 2016 ♦ 8:30 am – 1:30 pm                                    

7:00-8:00 am	Continental Breakfast and Check-in
8:00-8:15	Introduction to the Workshop	Ranjan Duara, MD Mount Sinai Medical Center
8:15-9:00	KEYNOTE LECTURE: KEYNOTE LECTURE: The Prevalence of Amyloid Positivity by Age, APOE Genotype and Cognitive Status - Implications for the Diagnosis of Alzheimer’s Disease	Philip Scheltens, MD, PhD VU University Medical Center
9:00-12:30	WORKSHOP: Diagnosis of Preclinical and Prodromal Alzheimer's Disease Chair: David Knopman, MD, Mayo Clinic Rochester
9:00-9:20	Biomarker Patterns in Subtypes of Alzheimer’s Disease - Implications for Pathophysiology and Diagnosis	Gil Rabinovici, MD University of California, San Francisco
9:20-9:40	Detection of Preclinical Alzheimer’s Disease: Implications for Prevention Trials	Reisa A. Sperling, MD, MMSc Massachusetts General Hospital/Harvard Medical School
9:40-10:00	The Added Value of the International Working Group - 2 Diagnostic Criteria for Alzheimer’s Disease	Bruno Dubois, MD Hôpital Pitié Salpêtrière
10:00-10:30	BREAK
10:30-10:50	Diagnostic Complexities in Current Clinical and Morphological Criteria for Alzheimer's Disease	Julie Schneider, MD Rush University Medical Center
10:50-11:10	A Canadian Consensus: Defining MCI for Clinical and Research Purposes	Howard Chertkow, MD McGill University and Jewish General Hospital
11:10-11:30	Harmonized Clinical Diagnostic Criteria for the Incipient Symptomatic Stages of Alzheimer’s Disease	John C. Morris, MD Washington University School of Medicine
11:30am-12:30pm	Workshop Discussion Moderator: David Knopman, MD, Mayo Clinic Rochester
12:30pm-1:30pm	LUNCH

The Annual Alzheimer’s Public Educational Forum:

Memory Complaints and the Early Diagnosis of Alzheimer’s Disease

Sunday, JANUARY 17, 2016 ♦ 1:30 pm – 5:40 pm                                 

1:00-1:30pm	Check-in and Refreshments
1:30-1:35	Welcome Notes	Ranjan Duara, MD Mount Sinai Medical Center
1:35-5:30	EDUCATIONAL FORUM: Memory Complaints and the Early Diagnosis of Alzheimer's Disease Chair: Steven T. DeKosky, MD, University of Florida
1:35-1:45	Introduction to the Educational Forum	Chair: Steven T. DeKosky, MD University of Florida
1:45-2:10	Alzheimer Disease: Between the Inevitable and the Modifiable	Vladimir Hachinski, CM, MD, DSc, FRCP University of Western Ontario
2:10-2:35	What are Subjective Memory Complaints and What is their Significance?	Ingmar Skoog, PhD Gothenburg University
2:35-3:00	Why is an Early Diagnosis of Alzheimer’s Important and How Do We Achieve It?	Frederick Schmitt, PhD University of Kentucky
3:00–3:30	BREAK
3:30 – 3:55	The Link Between Depression, Anxiety and Alzheimer’s Disease	Mary Ganguli, MD, MPH University of Pittsburgh
3:55-4:20	What have we Learned from Brain Autopsies of Persons with and without Dementia	David A. Bennett, MD Rush University Medical Center
4:20–4:45	The Importance of Participating in Clinical Trials in Alzheimer’s Disease	Amanda Smith, MD University of South Florida
4:45-5:30	Panel Discussion and Q&A Moderator: Steven T. DeKosky, MD, University of Florida

SUPPORTERS

---

This event is graciously underwritten by Marilyn and the late Myers Girsh.

---

The event is presented by:

Wien Center for Alzheimer’s Disease and Memory Disorders at Mount Sinai Medical Center.

http://www.msmc.com/neurosciences/wien-center-for-alzheimers-disease-memory-disorders

---

The event is made possible by educational grants from

Lilly USA, LLC.

www.lillygrantoffice.com

and from

Piramal Healthcare

www.piramal.com/imaging

---

MEDIA PARTNERS

Karger Publishers (www.karger.com)

Leaders Engaged on Alzheimer’s Disease (LEAD – www.leadcoalition.org)

Journal of Alzheimer’s Disease (www.j-alz.com)

The Academy of the American Board of Professional Neuropsychology (AABN – aabnonline.com)

ADDF’s 10th Annual Drug Discovery for Neurodegeneration Conference (www.worldeventsforum.com/addf/drugdiscovery)

10th Human Amyloid Imaging conference (www.worldeventsforum.com/hai)

The International Neuropsychological Society (www.the-ins.org)

Journal of Clinical and Experimental Neuropsychology (www.tandfonline.com/toc/ncen20/current)

Association of Neuropsychology Students in Training (www.div40-anst.com)

Hispanic Neuropsychological Society (HNPS – hnps.org)

13th Annual Mild Cognitive Impairment (MCI) Symposium:

Alzheimer and Non-Alzheimer’s Causes of MCI and Dementia  

Saturday, JANUARY 17, 2015  ♦  8:00 am – 7:30 pm                                

7:00-8:00	Continental Breakfast and Check-in
8:00am-8:15	Introduction to the Symposium	Ranjan Duara, MD, Mount Sinai Medical Center
8:15-9:00	KEYNOTE LECTURE: Assessing the Current Roadmap for Developing Novel Disease Modifying Therapies for Neurodegenerative Diseases	Todd E. Golde, MD, PhD University of Florida
9:00-12:30	MINISYMPOSIUM 1: Non-Alzheimer’s Dementias Chair: Todd E. Golde, MD, PhD University of Florida
9:00-9:25	Neurodegenerative Tauopathies – Clinicopathologic Correlations	Dennis W. Dickson, MD Mayo Clinic
9:25-9:50	Role of TDP-43 in Non-Alzheimer’s and Alzheimer’s Neurodegenerative Diseases	Keith A. Josephs, MD, MST, MSc Mayo Clinic
9:50-10:15	BREAK
10:15-10:40	Emerging Concepts in Chronic Traumatic Encephalopathy	Ann C. McKee, MD Boston University
10:40-11:05	New Approaches towards Interventions in Frontotemporal Dementia	Zachary A. Miller, MD University of California, San Francisco
11:05-11:30	How to Diagnose Early (Prodromal) Lewy Body Dementia	Ian McKeith, MD, FRC Psych, FSB, FMedSci Newcastle University
11:30am-12:30pm	Discussion Moderator: Rosa Rademakers, PhD Mayo Clinic
12:30-1:30	LUNCH
1:30-5:20	MINISYMPOSIUM 2: Clinical & Imaging Features of Prodromal Frontotemporal Lobar Degeneration Chair: Bradford C. Dickerson, MD Harvard University
1:30-1:55	Brain Networks in Neurodegenerative Disease	Michael D. Greicius, MD, MPH Stanford University
1:55-2:20	MCI of the FTLD type: Clinical Features and Imaging and Molecular Biomarkers	Bradford C. Dickerson, MD Harvard University
2:20-2:45	Imaging Characteristics of Prodromal Familial FTLD	Jonathan Rohrer, MD, PhD University College London
2:45-3:10	Clinical and Imaging Characteristics of Early bvFTD	Katya Rascovsky, PhD University of Pennsylvania
3:10-3:30	BREAK
3:30–3:55	Clinical and Imaging Features of Prodromal PPA	Emily J. Rogalski, PhD Northwestern University Feinberg School of Medicine
3:55-4:20	What is the Etiology of Amyloid Negative Mild Cognitive Impairment?	David A. Wolk, MD University of Pennsylvania
4:20-5:20	Discussion Moderator: Kimiko Domoto-Reilly, MD University of Washington, Seattle
5:20-7:30	NETWORKING RECEPTION

The Annual Early Alzheimer’s Diagnostic and Treatment Workshop:

Longitudinal and Cross Sectional Studies (Amyloid and Tau-Pet, Structural MRI, FDG-PET and Clinical Status  

Sunday, JANUARY 18, 2015 ♦ 8:30 am – 1:30 pm                                    

7:00-8:00 am	Continental Breakfast and Check-in
8:00-8:10	Introduction to the Workshop	Ranjan Duara, MD Mount Sinai Medical Center
8:10-8:55	KEYNOTE LECTURE: Longitudinal Changes in Autosomal Dominant AD: Implications for Treatment	John C. Morris, MD Washington University
8:55-12:30	WORKSHOP: Longitudinal and Cross Sectional Studies (Amyloid and Tau-Pet, Structural MRI, FDG-PET and Clinical Status) Chair: John C. Morris, MD Washington University
8:55-9:20	Correlating Cognition and Biomarkers in Preclinical APOE e4 and PS1 Mutation Carriers	Richard J. Caselli, MD Mayo Clinic Scottsdale
9:20-9:45	Cross-sectional and Longitudinal Imaging studies in Non-demented Subjects: Mayo Clinic Study of Aging	Prashanthi Vemuri, PhD Mayo Clinic
9:45-10:10	Understanding Biomarker Relationships in Alzheimer's Disease: The ADNI Experience	Susan M. Landau, PhD University of California, Berkeley
10:10-10:40	BREAK
10:40-11:05	Cross-sectional and Longitudinal Studies in LOAD: AIBL Experience	Christopher C. Rowe, MD, FRACP Austin Health
11:05-11:30	T807 Tau PET in Aging and Dementia	Keith A. Johnson, MD Massachusetts General Hospital
11:30 am-12:30 pm	Discussion Moderator: Reisa A. Sperling, MD, MMSc Harvard Medical School/MGH
12:30-1:30	LUNCH

The Annual Alzheimer’s Public Educational Forum:

Modifiable and Non-Modifiable Risk Factors for MCI and AD  

Sunday, JANUARY 18, 2015 ♦ 1:30 pm – 5:40 pm                                 

1:00-1:30 pm	Check-in and Refreshments
1:30 - 1:40	Welcome Notes	Ranjan Duara, MD Mount Sinai Medical Center
1:40-5:30	EDUCATIONAL FORUM: Modifiable and Non-Modifiable Risk Factors for MCI and AD Chair: Mary Ganguli, MD, MPH University of Pittsburgh
1:40-2:00	Introduction to the Educational Forum	Chair: Mary Ganguli, MD, MPH University of Pittsburgh
2:00-2:25	Factors which Modify Longevity in MCI and Dementia – the Mayo Clinic Experience	Ronald C. Petersen, MD, PhD Mayo Clinic
2:25-2:50	Personality, Lifestyle and Cognitive Health in Old Age	Robert S. Wilson, PhD Rush University Medical Center
2:50-3:15	Cognitive Engagement and Risk for MCI and Dementia	Robert Woods, PhD Bangor University
3:15-3:45	Break
3:45-4:10	Risk Factors for Dementia in the Oldest Old	Claudia H. Kawas, MD University of California, Irvine
4:10-4:35	How Does Exercise Benefit People at Risk for Dementia?	Neva Kirk-Sanchez, PhD, PT University of Miami
4:35-5:00	Vascular Factors which Modify Risk for Dementia	Sandra Black, MD, FRCP Sunnybrook Research Institute
5:00-5:40	Panel Discussion and Q&A	Moderator: Steven T. DeKosky, MD University of Pittsburgh Medical Center

SUPPORTERS

---

This event is graciously underwritten by Marilyn and the late Myers Girsh.

---

The event is presented by:

Wien Center for Alzheimer’s Disease and Memory Disorders at Mount Sinai Medical Center.

http://www.msmc.com/neurosciences/wien-center-for-alzheimers-disease-memory-disorders

---

The event is made possible by educational grants from

Lilly USA, LLC.

www.lillygrantoffice.com

and from

GE Healthcare

www3.gehealthcare.com

---

MEDIA PARTNERS

Karger Publishers (www.karger.com)

Leaders Engaged on Alzheimer’s Disease (LEAD – www.leadcoalition.org)

Journal of Alzheimer’s Disease (www.j-alz.com)

American Neuropsychiatric Association (ANPA – www.anpaonline.org)

Seniority Matters (www.senioritymatters.com)

PharmaVoice (www.pharmavoice.com)

30th International Conference on Alzheimer’s Disease International (www.alzint.org)

9th International Conference on FTD (www.ftdvancouver2014.com)

ADDF’s 9th Annual Drug Discovery for Neurodegeneration Conference (www.worldeventsforum.com/addf/drugdiscovery)

9th Human Amyloid Imaging conference (www.worldeventsforum.com/hai).

12th Annual Mild Cognitive Impairment (MCI) Symposium:

Predicting and Measuring Progression in Early Alzheimer’s Disease (AD)  

Saturday, JANUARY 18, 2014 ♦ 8:00 am – 7:30 pm

8:00 – 8:10 am	Introduction to the MCI Symposium 2014	Ranjan Duara, MD Mount Sinai Medical Center, Miami Beach, FL
8:15 – 8:55	Keynote Address The Relationship between Aβ Deposition, Neurodegeneration and Cognitive Function in Normal and Impaired Individuals	Clifford R. Jack, MD Mayo Clinic
8:55 – 11:40 am	MiniSymposium 1 A-beta Deposition, Neurodegeneration and Cognitive Function in Normal and Abnormal Aging Chair:	Chester Mathis, PhD University of Pittsburgh
	Current models of Alzheimer’s Disease (AD) suggest amyloid deposition is the first in a chain of events which ultimately lead to neurodegeneration and progressive cognitive and functional deterioration. It appearsthat most of the cognitive effects of Aβ deposition are associated with neurodegeneration, although Aβ itself may cause subtle cognitive impairment, independent of neurodegeneration.Evidence of Aβ deposition (amyloid positive status) in the brain is present on PET scans or CSF studies among 90 to 95% of individuals with clinically diagnosed Alzheimer’s disease, almost all of whom will also have evidence of neurodegeneration, as evidenced by hippocampal atrophy and/or cortical atrophy in AD signature neocortical regions. Among subjects with amnestic MCI only about 50 to 60% are found to be amyloid positive, whereas the frequency of neurodegeneration on MRI scans among aMCI subjects appears to be 80 to 85%. Based on the hypothesis that Aβ deposition initiates the neurodegenerative process in AD, it would be expected that amyloid biomarkers should be positive (Amy+ status) more frequently than biomarkers of neurodegeneration (i.e., MRI+ status), especially in the predementia phases of Alzheimer’s disease. Results from several groups suggest that MRI+ status occurs more frequently than Amy+ status among subjects with MCI. While the presence of non-AD conditions, such as hippocampal sclerosis and frontotemporal dementias may be responsible, in part, for the higher frequency of MRI+ status, it seems unlikely that the prevalence of non-AD neurodegenerative conditions would be so high among elderly individuals in the MCI stage of impairment. Alternative explanations for this apparently aberrant sequence of biomarker changes should be considered. The relationship between Aβ deposition in the brain and the onset of neurodegeneration may be influenced by a variety of factors, intrinsic and extrinsic to the brain. These include the Aβ load (much higher in dominantly inherited AD than sporadic AD), the age of the individual, the influence of various AD risk genes, individual lifestyles (diet, levels of physical and cognitive activity and socialization), the presence of depression and anxiety and systemic illnesses, such as hypertension, cardiovascular disease and chronic inflammatory conditions. These factors may have a bearing on the sequence of biomarker and cognitive changes which appear as an individual progresses from preclinical to clinical AD. In this MiniSymposium we will explore relationships between amyloid deposition, neurodegeneration and cognitive impairment.
8:55 – 9:20	1. Amyloid, Glucose Metabolism, and Longitudinal Change	Susan Landau, PhD University of California, Berkeley
9:20 – 9:45	2. Beta Amyloid Deposition in Very Healthy Adults: Risk Factors and Cognitive Consequences	Denise C. Park, PhD University of Texas, Dallas, TX
9:45 – 10:10	3. The Role of Imaging Biomarkers in the Prediction of MCI and Dementia Due to AD	Ronald Petersen, MD Mayo Clinic
10:30 – 10:55	4. Variation in the Sequence of AD Biomarkers According to Brain Regions and Genetic Factors	Gaël Chételat, PhD Inserm-EPHE-Université de Caen, Basse-Normandie
10:55 – 11:20	5. Cognitive Correlates of Neurodegeneration Related to Beta-amyloid and Aging in Clinically Normal Individuals	Elizabeth Mormino, PhD Massachusetts General Hospital
11:20 – 11:45	6. Clinical Implications of Concordant and Discordant Beta-Amyloid and Neurodegenerative Abnormalities in Mild Cognitive Impairmen	David A. Wolk, MD University of Pennsylvania
11:45 am – 12:45 pm	Discussion	Discussant: William Klunk, MD, PhD University of Pittsburgh
1:45 – 4:30	MiniSymposium 2 Approaches to Measuring Cognitive and Functional Change across the MCI Spectrum	Chair: David Loewenstein, PhD, ABPP University of Miami
	The diagnosis of cognitive states relies on two pillars of clinical assessment, namely, the history from the subject (and/or one or more informants), providing information about the presence, severity and course of functional impairment, and an objective cognitive (neuropsychological) assessment. Heterogeneity in progression rates in MCI and dementia may reflect intrinsic variability, error in the measurement of cognitive and functional status,due to a number of factors, including: (1) cognitive reserve (2) language and cultural factors (3) socioeconomic status (4) motivation (5) informant bias (6) co-morbid medical, neurological and psychiatric conditions. The inclusion of biomarkers, which are not affected by the above mentioned factors, in the diagnostic process has improved the identification of individuals with very early stages of AD. Biomarkers are also sensitive for detecting pre-dementia conditions but there are no validated biomarkers for measuring progression rates in AD. It is important, therefore, to seek out clinical measures which are sensitive for measuring progression in very early stages of disease. Although clinical outcomes, such as functional change, are subject to measurement error, at this time they remain the most important methods for measuring progression in pre-dementia states. The optimal methods for assessing cognitive and functional progression, including the use of composite scores for measuring global change in pre-dementia conditions and for demonstrating treatment effects in clinical trials is an active area of research. In this MiniSymposium, current research exploring the utility of various clinical measures, and their correlation with rates of progression indicated by biomarkers, will be addressed.
1:45 – 2:05	1. Development of Novel Paradigms for Assessing and Monitoring Cognitive Change Across the MCI and PreMCI Spectrum	David Loewenstein, PhD, ABPP University of Miami
2:05 – 2:30	2. Biomarker Values Predictive of Cognitive Decline in MCI: Baseline or Progression?	Hiroko H. Dodge, PhD Oregon Health & Science University
2:30 – 2:55	3. Computer-Based Assessment of ADLs and IADLs in MCI	Sara Czaja, PhD University of Miami
2:55 – 3:20	4. On Cognitive Performance as the Endpoint in Clinical Trials	Ben Schmand, PhD University of Amsterdam
3:40 – 4:05	5. Cognitive Trajectories Associated with β-amyloid Deposition in Normal Aging and MCI	Beth Snitz, PhD University of Pittsburgh
4:05 – 4:30	6. Probability of Transition To and From MCI: Models of Clinical and Cognitive Features	Frederick Schmitt, PhD University of Kentucky
4:30 – 5:30	Discussion	Discussant: Mary Ganguli, MD, MPH University of Pittsburgh
5:30 – 7:30	NETWORKING RECEPTION

3rd Annual Early Alzheimer’s Diagnostic and Treatment Workshop:

Diagnostic Case Studies of Preclinical Alzheimer’s Disease (AD), MCI-AD and Probable AD  

Sunday, JANUARY 19, 2014 ♦ 8:30 am – 1:30 pm

8:30 – 8:35	Introduction to the Workshop	Ranjan Duara, MD Mount Sinai Medical Center, Miami Beach, FL
8:35 – 9:15	KEYNOTE LECTURE Challenges in the Diagnosis of Early Alzheimer’s Disease	Stephen Salloway, MD The Warren Alpert Medical School of Brown University
9:15 – 11:30	DIAGNOSTIC CASE STUDIES OF PRECLINICAL AD, MCI-AD AND PROBABLE AD Cases with concordant and discordant biomarkers and clinical results will be discussed. Several cases with follow-up to autopsy will be included.	Chair: Howard Chertkow, MD, McGill University and Jewish General Hospital
9:15 – 9:35	Case 1: Clinical Implications of Discordant Biomarkers	David A. Wolk, MD University of Pennsylvania
9:35 – 9:55	Case 2: A Case of Vascular MCI	Charles DeCarli, MD University of California, Davis
9:55 – 10:15	Case 3: Conflicting Biomarkers in Clinical Practice	Philip Scheltens, MD, PhD VU University Amsterdam
10:15 – 10:30	BREAK
10:30 – 10:50	Case 4: Longitudinal Cognitive and Imaging Changes in a 70 y/o woman with Initial Subjective Cognitive Concerns	Dorene Rentz, PsyD Harvard Medical School/Brigham and Women's Hospital
10:50 – 11:10	Case 5: When Amyloid Imaging Isn’t Enough	Tammie Benzinger, MD, PhD Washington University School of Medicine
11:10 – 11:30	Case 6: Biomarker Use to Assist in Diagnosis of Atypical MCI Presentations/ Imaging for Identifying non-AD	Adam S. Fleisher, MD Banner Alzheimer's Institute
11:30 am – 12:30 pm	Open Discussion
12:30 – 1:30	LUNCH

2nd Annual Early Alzheimer’s Public Education Forum

The Role of Amyloid Imaging in the Diagnosis of Mild Cognitive Impairment 

Sunday, JANUARY 19, 2014 ♦ 1:30 pm – 5:30 pm

---

 

The Early Alzheimer’s Public Educational Forum is intended for the public at large, including individuals at-risk for Alzheimer’s disease, their family members, as well as professionals from various fields who may be interested in an up-to-date review of some aspects of Alzheimer’s research. This educational segment aims to provide information about the latest research in the field of diagnosis of Alzheimer’s disease, including the use of amyloid imaging for this purpose. The forum will allow the audience to interact with top scientists in the field in the presence of a moderator.

1:30 – 1:40 pm	Welcome Notes	Ranjan Duara, MD Mount Sinai Medical Center
1:40 – 2:00	Introduction to the Educational Forum	Stephen Salloway, MD The Warren Alpert Medical School of Brown University
2:00 – 4:25	The Role of Amyloid Imaging in the Diagnosis of Mild Cognitive Impairment	Chair: Stephen Salloway, MD, MS The Warren Alpert Medical School of Brown University
2:00 – 2:25	Incorporating Biomarkers of Amyloid and Neurogeneration in Clinical Evaluation of Mild Cognitive Impairment	David A. Wolk, MD University of Pennsylvania
2:25 – 2:50	The Role of Cognitive Reserve in the Clinical Presentation of Alzheimer’s Disease	Dorene Rentz, PsyD Harvard Medical School/Brigham and Women’s Hospital
2:50 – 3:10	BREAK	Michael D. Devous, PhD Avid Radiopharmaceuticals
3:10 – 3:35	Amyloid Imaging in Healthy Aging: Impact on Brain Function and Cognition	Stephen Salloway, MD The Warren Alpert Medical School of Brown University
3:35 – 4:00	Challenges in the Diagnosis of Early Alzheimer’s Disease	Adam S. Fleischer, MD, MAS Banner Alzheimer’s Institute
4:00 – 4:25	The Role of Amyloid Imaging in the Diagnosis of Mild Cognitive Impairment: Current Research and Clinical Utility	Panel Discussion and Q&A Panelists: Michael Devous, PhD, Avid Radiopharmaceuticals Keith Fargo, PhD, Alzheimer’s Association Adam S. Fleisher, MD, MAS, Banner Alzheimer’s Institute Dorene Rentz, PsyD, Harvard Medical School/Brigham and Women’s Hospital Stephen Salloway, MD, The Warren Alpert Medical School of Brown University David A. Wolk, MD, University of Pennsylvania
5:25 – 5:30	Closing Notes	Ranjan Duara, MD Mount Sinai Medical Center

11th Annual Mild Cognitive Impairment (MCI) Symposium:

Predicting and Measuring Progression in Early Alzheimer’s Disease (AD)

Saturday, JANUARY 19, 2013 ♦ 7:00 am – 7:30 pm

7:00 – 8:00 am	Check-in and Breakfast
8:00 – 8:15	Welcome and Introduction	Ranjan Duara, MD Mount Sinai Medical Center, Miami Beach, FL
8:15 – 10:45	Minisymposium 1 Predictors of Progression to MCI and AD (Epidemiology)	Chair: Mary Ganguli, MD, MPH University of Pittsburgh, Pittsburgh, PA
	1. New Approaches to Understanding the Relationships of Risk Factors to Cognitive Decline	David A. Bennett, MD Rush Medical School, Chicago, IL
	2. The Flynn Effect; How Secular Changes Influence the Predictive Value of Cognitive Performance and the Role of Computer Tomography in Prodromal Dementia in the H70 Study in Gothenburg, Sweden	Simona Sacuiu, MD, PhD Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
	3. Rates and Predictors of Progression from Mild Cognitive Impairment to Dementia: The Mayo Clinic Study of Aging	Rosebud Roberts, MB, ChB Mayo Clinic, Rochester, MN
	4. Risk Factors for Age of Onset of AD in the Cache County Study	Peter Rabins, MD, MPH Johns Hopkins University, Baltimore, MD
	5. The Fluidity of MCI in the Community and the Role of Vascular Biomarkers in Predicting Progression in the Indianapolis-Ibadan Study	Hugh Hendrie, MB, ChB, DSc Indiana University, Indianapolis, IN
	6. Risk Factors for MCI Development and for MCI Progression: Are They The Same?	Mary Ganguli, MD, MPH University of Pittsburgh, Pittsburgh, PA
10:45 – 11:00	Break
11:00 am – 12:00 pm	Open Discussion	Discussant: Ronald Petersen, MD, PhD Mayo Clinic, Rochester, MN
12:00 – 1:00	LUNCH
1:00 – 2:00	Keynote Lecture: Solving the Dilemma of Treatment Versus Prevention Strategies for Alzheimer’s Disease	Todd Golde, MD, PhD University of Florida, Gainesville, FL
2:00 – 4:15	Mini – Symposium 2 Utility of Biomarkers for Predicting and Measuring Progression in Normal Aging, MCI and AD	Chair: Tammie Benzinger, MD, PhD Washington University School of Medicine, St. Louis, MO
	1. The Cortical Signatures of Alzheimer’s Disease and Frontotemporal Degeneration: Quantitative MRI Biomarkers Detectable prior to Dementia	Brad Dickerson, MD, MMSc Harvard Medical School, Boston, MA
	2. Biomarkers, Cognitive Reserve and Cognition in Alzheimer’s Disease	Prashanthi Vemuri, PhD Mayo Clinic, Rochester, MN
	3. Neuroimaging for Predicting and Measuring Progression in Preclinical Autosomal Dominant Alzheimer’s Disease	Tammie Benzinger, MD, PhD Washington University School of Medicine, St. Louis, MO
	4. MRI, FDG-PET and EEG for Predicting Progression in Aging, MCI and AD	Philip Scheltens, MD, PhD VU Medical Center, Amsterdam, Netherlands
	5. Highlights of Biomarker and Clinical Outcomes from Recent AD Treatment Trials	Stephen Salloway, MD, MS Brown Medical School, Providence, RI
4:15 – 4:30	Break
4:30 – 5:30	Open Discussion	Discussant: Victor Villemagne, MD, Austin Health, University of Melbourne, Melbourne, Australia
5:30 – 7:30	NETWORKING RECEPTION

Early Alzheimer’s Disease Workshop:

Alzheimer’s Disease Prevention Trials

Sunday, JANUARY 20, 2013 ♦ 8:00 am – 1:30 pm

7:00 – 8:00 am	Check-in and Breakfast
8:00 am – 8:10	Introduction to the Workshop	Ranjan Duara, MD Mount Sinai Medical Center, Miami Beach, FL
8:10 – 9:00 am	Keynote Lecture: Launching the Era of Alzheimer’s Prevention Research	Eric M. Reiman, MD Banner Alzheimer’s Institute, Phoenix, AZ
9:00 – 11:15am	Challenges in Treating Preclinical Alzheimer’s Disease Chair: Reisa A. Sperling, MD, MMSc, Massachusetts General Hospital and Harvard Medical School, Boston, M	Chair: Reisa A. Sperling, MD, MMSc, Massachusetts General Hospital and Harvard Medical School, Boston, MA
	1. A New Era: DIAN and the Secondary Prevention of Symptomatic Alzheimer’s Disease	John C. Morris, MD Washington University School of Medicine, St. Louis, MO
	2. Anti-Amyloid Treatment of Asymptomatic Alzheimer’s Disease: The A4 Study	Reisa A. Sperling, MD, MMSc, Massachusetts General Hospital and Harvard Medical School, Boston, MA
	3. The Role of Fluid Biomarkers in Preclinical Alzheimer’s Treatment Trials	Anne M. Fagan, PhD Washington University School of Medicine, St. Louis, MO
	4. The Role of Amyloid Imaging in Preclinical Alzheimer’s Treatment Trials	Adam S. Fleisher, MD, MAS Banner Alzheimer’s Institute, Phoenix, AZ
	5. Addressing the Ethical Challenges of Preclinical AD Prevention Trials	Jason Karlawish, MD University of Pennsylvania School of Medicine, Philadelphia, PA
	6. Consent for Revealing Biomarker Status in AD Prevention Trials	Scott Roberts, PhD University of Michigan School of Public Health, Ann Arbor, MI
11:15am – 11:30	Break
11:30am – 12:30 pm	Open Discussion Discussant: Philip Scheltens, MD, PhD VU Medical Center, Amsterdam, Netherlands
12:30 – 1:30 pm	LUNCH

Alzheimer’s Public Educational Forum:

Alzheimer’s Disease Prevention Trials

Sunday, JANUARY 20, 2013 ♦ 2:00 pm – 5:30 pm

2:00 – 2:10 pm	Introduction to the Educational Forum	Ranjan Duara, MD Mount Sinai Medical Center, Miami Beach, FL
2:10 – 4:30 pm	Alzheimer’s Disease Prevention Trials	Chair: Eric M. Reiman, MD, Banner Alzheimer’s Institute, Phoenix, AZ
	Measuring Progression in Alzheimer’s Disease Using Brain Imaging Tests	Susan Landau, PhD University of California, Berkeley, CA
	Q&A
	Treating Alzheimer’s Before Symptoms Begin	Reisa A. Sperling, MD, MMSc, Massachusetts General Hospital and Harvard Medical School, Boston, MA
	Q&A
	What We Know About the Genetics of Alzheimer’s Disease	Allan Levey, MD, PhD Emory University School of Medicine, Atlanta, GA
	Q&A
	The Importance of Being Informed and Participating in Trials
	Q&A
4:30 – 5:30 pm	Questions from the Audience and Panel Discussion	Panelists: Maria Carrillo, John C. Morris, Steve Salloway, Eric Reiman, Reisa A. Sperling, Scott Roberts

---

SUPPORTERS

This event was graciously underwritten by Marilyn and the late Myers Girsh.

The event was presented by

10th Annual Mild Cognitive Impairment (MCI) Symposium

January 14-15, 2012

 

9th Annual Mild Cognitive Impairment (MCI) Symposium

April 29-30, 2011

8th Annual Mild Cognitive Impairment (MCI) Symposium

March 12-13, 2010

7th Annual Mild Cognitive Impairment (MCI) Symposium

March 27-28, 2009

6th Annual Mild Cognitive Impairment (MCI) Symposium

March 7-8, 2008

5th Annual Mild Cognitive Impairment (MCI) Symposium

April 13-14, 2007

4th Annual Mild Cognitive Impairment (MCI) Symposium

February 24-25, 2006

3rd Annual Mild Cognitive Impairment (MCI) Symposium

March 11-12, 2005

2nd Annual Mild Cognitive Impairment (MCI) Symposium

February 27-28, 2004